HER-2 Positive Breast Cancer Market in the US 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Pathophysiology
06.3 Epidemiology
06.4 Diagnosis
06.4.1 IHC
06.4.2 FISH
06.4.3 SPoT-Light HER-2 CISH Test (Subtraction Probe Technology Chromogenic In Situ Hybridization)
06.4.4 Inform HER-2 Dual ISH Test (Inform Dual In Situ Hybridization)
06.5 Management
06.5.1 Surgery
06.5.2 Radiotherapy
06.5.3 Chemotherapy
06.5.4 Targeted Therapy
06.5.5 Hormonal Therapy
06.6 Economic Burden
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Type of Therapy
08.1 Chemotherapy
08.1.1 Alkylating Agents
08.1.2 Antimetabolites
08.1.3 Cytotoxic Antibiotics
08.1.4 Taxanes
08.2 Targeted Therapy
08.3 Hormone Therapy
09. 9 Market Segmentation by Molecule Type
09.1 Biologics
09.2 Small Molecules
10 Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11 Buying Criteria
12 Market Growth Drivers
13 Drivers and their Impact
14 Market Challenges
15 Impact of Drivers and Challenges
16 Market Trends
17 Trends and their Impact
18 Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Competitive Assessment of the Top Drugs
18.2.2 Celgene
18.2.3 F. Hoffmann-La Roche
18.2.4 GlaxoSmithKline
18.2.5 Novartis
18.2.6 Sanofi
18.3 Other Prominent Vendors
19 Key Vendor Analysis
19.1 Celgene
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Strategy
19.1.4 Business Segmentation by Revenue
19.1.5 Sales by Geography
19.1.6 Key Information
19.1.7 SWOT Analysis
19.2 F. Hoffmann-La Roche
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Sales by Geography
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.3 GlaxoSmithKline
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Pipeline Products
19.3.7 Business Strategy
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Novartis
19.4.1 Key Facts
19.4.2 Business Description
19.4.3 Business Segmentation
19.4.4 Revenue by Business Segmentation
19.4.5 Revenue Comparison 2012 and 2013
19.4.6 Sales by Geography
19.4.7 Business Strategy
19.4.8 Key Developments
19.4.9 SWOT Analysis
19.5 Sanofi
19.5.1 Key Facts
19.5.2 Business Description
19.5.3 Business Segmentation
19.5.4 Revenue by Business Segmentation
19.5.5 Revenue Comparison 2012 and 2013
19.5.6 Sales by Geography
19.5.7 Business Strategy
19.5.8 Key Developments
19.5.9 SWOT Analysis
20 Other Reports in this Series